Dnaprint Genomics Stock Performance
DNAPrint Genomics holds a performance score of 10 on a scale of zero to a hundred. The firm owns a Beta (Systematic Risk) of -66.99, which means a somewhat significant risk relative to the market. As returns on the market increase, returns on owning DNAPrint Genomics are expected to decrease by larger amounts. On the other hand, during market turmoil, DNAPrint Genomics is expected to outperform it. Use DNAPrint Genomics coefficient of variation, as well as the relationship between the total risk alpha and kurtosis , to analyze future returns on DNAPrint Genomics.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in DNAPrint Genomics are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite nearly unfluctuating basic indicators, DNAPrint Genomics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
DNAPrint Genomics Relative Risk vs. Return Landscape
If you would invest 0.00 in DNAPrint Genomics on October 11, 2025 and sell it today you would earn a total of 0.00 from holding DNAPrint Genomics or generate 9.223372036854776E16% return on investment over 90 days. DNAPrint Genomics is currently generating 16.129% in daily expected returns and assumes 127.0001% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than DNAPrint, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
DNAPrint Genomics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for DNAPrint Genomics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as DNAPrint Genomics, and traders can use it to determine the average amount a DNAPrint Genomics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.127
| High Returns | Best Equity | DNAG | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average DNAPrint Genomics is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of DNAPrint Genomics by adding it to a well-diversified portfolio.
DNAPrint Genomics Fundamentals Growth
DNAPrint Stock prices reflect investors' perceptions of the future prospects and financial health of DNAPrint Genomics, and DNAPrint Genomics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on DNAPrint Stock performance.
| Return On Asset | -1.05 | ||||
| Profit Margin | (2.36) % | ||||
| Operating Margin | (7.31) % | ||||
| Current Valuation | 5.64 M | ||||
| Price To Sales | 0.20 X | ||||
| Revenue | 2.43 M | ||||
| EBITDA | (5.78 M) | ||||
| Cash And Equivalents | 134.35 K | ||||
| Total Debt | 240 K | ||||
| Book Value Per Share | (0.01) X | ||||
| Cash Flow From Operations | (5.78 M) | ||||
| Total Asset | 10.27 M | ||||
| Retained Earnings | (45.53 M) | ||||
| Current Asset | 1.89 M | ||||
| Current Liabilities | 11.24 M | ||||
About DNAPrint Genomics Performance
By analyzing DNAPrint Genomics' fundamental ratios, stakeholders can gain valuable insights into DNAPrint Genomics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if DNAPrint Genomics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if DNAPrint Genomics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
DNAPrint Genomics, Inc. engages in the development and marketing of genetic testing products and services. The company was incorporated in 1983 and is based in Sarasota, Florida with a subsidiary in Leverkusen, Germany. DNAPRINT GENOMICS is traded on OTC Exchange in the United States.Things to note about DNAPrint Genomics performance evaluation
Checking the ongoing alerts about DNAPrint Genomics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for DNAPrint Genomics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| DNAPrint Genomics is way too risky over 90 days horizon | |
| DNAPrint Genomics has some characteristics of a very speculative penny stock | |
| DNAPrint Genomics appears to be risky and price may revert if volatility continues | |
| DNAPrint Genomics has high likelihood to experience some financial distress in the next 2 years | |
| DNAPrint Genomics currently holds 240 K in liabilities. DNAPrint Genomics has a current ratio of 0.17, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about DNAPrint Genomics' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 2.43 M. Net Loss for the year was (12.35 M) with profit before overhead, payroll, taxes, and interest of 446.37 K. | |
| DNAPrint Genomics currently holds about 134.35 K in cash with (5.78 M) of positive cash flow from operations. | |
| DNAPrint Genomics has a frail financial position based on the latest SEC disclosures |
- Analyzing DNAPrint Genomics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether DNAPrint Genomics' stock is overvalued or undervalued compared to its peers.
- Examining DNAPrint Genomics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating DNAPrint Genomics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of DNAPrint Genomics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of DNAPrint Genomics' stock. These opinions can provide insight into DNAPrint Genomics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for DNAPrint Stock analysis
When running DNAPrint Genomics' price analysis, check to measure DNAPrint Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DNAPrint Genomics is operating at the current time. Most of DNAPrint Genomics' value examination focuses on studying past and present price action to predict the probability of DNAPrint Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DNAPrint Genomics' price. Additionally, you may evaluate how the addition of DNAPrint Genomics to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |